X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (229) 229
nvp-bez235 (215) 215
humans (210) 210
oncology (168) 168
cell line, tumor (125) 125
tor serine-threonine kinases - antagonists & inhibitors (123) 123
imidazoles - pharmacology (107) 107
animals (106) 106
phosphatidylinositol 3-kinases - antagonists & inhibitors (105) 105
quinolines - pharmacology (105) 105
cancer (98) 98
pi3k (98) 98
female (90) 90
mtor (90) 90
apoptosis (87) 87
bez235 (86) 86
mice (79) 79
signal transduction - drug effects (78) 78
tor serine-threonine kinases - metabolism (78) 78
phosphatidylinositol 3-kinases - metabolism (75) 75
cell proliferation - drug effects (71) 71
rapamycin inhibitor (70) 70
phosphatidylinositol 3-kinase/mammalian target (67) 67
antineoplastic agents - pharmacology (66) 66
growth (65) 65
pathway (64) 64
protein kinase inhibitors - pharmacology (61) 61
cell biology (58) 58
phosphorylation (57) 57
mammalian target (56) 56
proto-oncogene proteins c-akt - metabolism (55) 55
apoptosis - drug effects (51) 51
akt (49) 49
kinases (48) 48
rapamycin (48) 48
xenograft model antitumor assays (48) 48
drug synergism (47) 47
resistance (46) 46
signal transduction (46) 46
breast cancer (43) 43
tumors (43) 43
mutation (42) 42
autophagy (41) 41
chemotherapy (41) 41
dual pi3k/mtor inhibitor (41) 41
male (40) 40
mutations (40) 40
activation (39) 39
in-vivo (38) 38
proteins (36) 36
analysis (35) 35
mice, nude (35) 35
cells (34) 34
care and treatment (32) 32
expression (32) 32
research (32) 32
antitumor-activity (31) 31
breast-cancer (31) 31
everolimus (31) 31
pharmacology & pharmacy (31) 31
biochemistry & molecular biology (30) 30
inhibitor nvp-bez235 (30) 30
article (29) 29
cancer therapies (29) 29
health aspects (29) 29
genetic aspects (28) 28
imidazoles - administration & dosage (28) 28
quinolines - administration & dosage (28) 28
1-phosphatidylinositol 3-kinase (27) 27
antineoplastic combined chemotherapy protocols - pharmacology (27) 27
phosphatidylinositol 3-kinase - antagonists & inhibitors (27) 27
antineoplastic agents - therapeutic use (26) 26
dose-response relationship, drug (26) 26
imidazoles - therapeutic use (26) 26
therapy (26) 26
tor protein (26) 26
breast neoplasms - drug therapy (25) 25
cancer-cells (25) 25
cell growth (25) 25
cell proliferation (25) 25
cell survival - drug effects (25) 25
quinolines - therapeutic use (25) 25
cell cycle (24) 24
proto-oncogene proteins c-akt - antagonists & inhibitors (24) 24
inhibitors (22) 22
protein kinase inhibitors - therapeutic use (22) 22
drug resistance (21) 21
sirolimus - pharmacology (21) 21
development and progression (20) 20
phosphatidylinositol 3-kinases - genetics (20) 20
phosphorylation - drug effects (20) 20
drug resistance, neoplasm (19) 19
phosphatidylinositol 3-kinase - metabolism (19) 19
research paper (19) 19
breast neoplasms - pathology (18) 18
cancer research (18) 18
clinical trials (18) 18
disease models, animal (18) 18
drug resistance, neoplasm - drug effects (18) 18
enzyme inhibitors - pharmacology (18) 18
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Biochemical Journal, ISSN 0264-6021, 08/2011, Volume 438, Issue 1, pp. 53 - 62
Genetic alterations in PI3K (phosphoinositide 3-kinase) signalling are common in cancer and include deletions in PTEN (phosphatase and tensin homologue deleted... 
Phosphoinositide 4-kinase (PI4K) | Pan-phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor NVP-BEZ235; phosphoinositide 3-kinase α (PI3Kα) | PIK3CA | p110α E545k mutation | PIK3CA H1047R mutation | 3T3-L1 ADIPOCYTES | CATALYTIC SUBUNIT | BIOCHEMISTRY & MOLECULAR BIOLOGY | p110 alpha E545K mutation | phosphoinositide 4-kinase (PI4K) | pan-phosphoinositide 3-kinase (PI3K)/mammalian target of rapamycin (mTOR) inhibitor NVP-BEZ235 | BREAST-CANCER | INSULIN | P110-BETA | phosphoinositide 3-kinase alpha (PI3K alpha) | PIK3CA GENE | IN-VIVO | MUTATIONS | INHIBITORS | IA PI3K ISOFORMS | Class Ia Phosphatidylinositol 3-Kinase - metabolism | Humans | Neoplasms, Experimental - prevention & control | Enzyme Inhibitors - therapeutic use | Class Ia Phosphatidylinositol 3-Kinase - antagonists & inhibitors | Mice, Knockout | Neoplasms, Experimental - pathology | Tissue Distribution | Animals | Enzyme Inhibitors - pharmacokinetics | Signal Transduction - drug effects | Protein Isoforms | Mice | Neoplasms, Experimental - metabolism | Tumor Cells, Cultured | Homeodomain Proteins - physiology | Proto-Oncogene Proteins c-akt - metabolism | Proto-Oncogene Proteins c-akt - antagonists & inhibitors | Index Medicus | PI3K, phosphoinositide 3-kinase | BID, twice daily dosing | p110α E545K mutation | mammalian target of rapamycin (mTOR) inhibitor NVP-BEZ235; phosphoinositide 3-kinase α (PI3Kα) | PTEN, phosphatase and tensin homologue deleted on chromosome 10 | ERK, extracellular-signal-regulated kinase | PKB, protein kinase B | pan-phosphoinositide 3kinase (PI3K) | PI4K, phosphoinositide 4-kinase | QD, once daily dosing | mTOR, mammalian target of rapamycin | TGI, tumour growth inhibition
Journal Article
Science Translational Medicine, ISSN 1946-6234, 07/2018, Volume 10, Issue 449, p. eaaq1564
Inhibition of the mechanistic target of rapamycin (mTOR) protein kinase extends life span and ameliorates aging-related pathologies including declining immune... 
RAPAMYCIN | TARGET | MEDICINE, RESEARCH & EXPERIMENTAL | DISEASE | GROWTH | NVP-BEZ235 | RESISTANCE | MTOR | CELL BIOLOGY
Journal Article
by Xin P and Xu W and Zhu X and Li C and Zheng Y and Zheng T and Cheng W and Peng Q
Cancer Management and Research, ISSN 1179-1322, 08/2019, Volume 11, pp. 7933 - 7951
Pengliang Xin,1 Wenqian Xu,1 Xiongpeng Zhu,1 Chuntuan Li,1 Yan Zheng,1 Tingjin Zheng,2 Wenzhao Cheng,3 Qunyi Peng11Department of Haematology, Quanzhou First... 
autophagy | proliferation | BEZ235 | chronic myelogenous leukemia | apoptosis
Journal Article
NANO RESEARCH, ISSN 1998-0124, 09/2018, Volume 11, Issue 9, pp. 4846 - 4858
Seeking profitable therapies for triple-negative breast cancer (TNBC) has attracted intense research interest. However, an efficient cure for TNBC remains an... 
triple-negative breast cancer | PHYSICS, APPLIED | SUBTYPES | PROGNOSIS | photodynamic therapy | MATERIALS SCIENCE, MULTIDISCIPLINARY | DNA-DAMAGE | NVP-BEZ235 | CHEMISTRY, PHYSICAL | nanomedicine | NANOSCIENCE & NANOTECHNOLOGY | synergistic therapy | OPPORTUNITIES | CHALLENGES | PATHWAY | PI3K/MTOR INHIBITOR NVP-BEZ235 | STRESS | PROMOTES
Journal Article
Cancers, 08/2019, Volume 11, Issue 8, p. 1204
Our previous study demonstrated that administration of NVP-BEZ235 (BEZ235), a dual PI3K/mTOR inhibitor, before radiotherapy (RT) enhanced the radiotherapeutic... 
PI3K/mTOR | colorectal cancer | radiation | BEZ235 | maintenance
Journal Article
by Ma, YY and Jin, ZX and Yu, K and Liu, QF
AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, ISSN 1943-8141, 2019, Volume 11, Issue 1, pp. 87 - 105
Background: The PI3K/Akt/mTOR pathway is constitutively activated in human multiple myeloma (MM) cell lines and in freshly isolated plasmocytes from patients... 
MEDICINE, RESEARCH & EXPERIMENTAL | CELLS | multiple myeloma | ACTIVATION | autophagy | INDUCED APOPTOSIS | NVP-BEZ235 | BEZ235 | apoptosis | AKT | ONCOLOGY | IN-VIVO | mTOR | pathway | PROTECTIVE AUTOPHAGY | FOXO3A | mechanism | MTOR INHIBITOR
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 04/2011, Volume 17, Issue 8, pp. 2373 - 2384
Journal Article
Oncotarget, ISSN 1949-2553, 2017, Volume 8, Issue 64, pp. 107977 - 107990
Dysregulation of the phosphatidylinositol 3-kinase (PI3K) pathway occurs frequently in human cancer and contributes to resistance to antitumor therapy.... 
BEZ235 | PI3K | Drug resistance | MTOR | SHR8443 | CELLS | MUTANT BREAST-CANCER | PI3K INHIBITORS | NVP-BEZ235 | ANTITUMOR-ACTIVITY | PI3K/MTOR INHIBITOR | CELL BIOLOGY | POTENT INHIBITOR | PATHWAY | 3-KINASE/MAMMALIAN TARGET | mTOR | RESISTANCE | drug resistance
Journal Article
Journal Article
JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0022-2623, 07/2019, Volume 62, Issue 13, pp. 6241 - 6261
The phosphoinositide 3-kinase (PI3K)/mechanistic target of rapamycin (mTOR) pathway is frequently overactivated in cancer, and drives cell growth,... 
NVP-BYL719 | CHEMISTRY, MEDICINAL | PQR309 | METABOLISM | 3-KINASE/MAMMALIAN TARGET | GROWTH | NVP-BEZ235 | IDENTIFICATION | PI3K/MTOR INHIBITOR | PHOSPHOINOSITIDE 3-KINASE | WORTMANNIN
Journal Article
Nagoya Journal of Medical Science, ISSN 0027-7622, 02/2019, Volume 81, Issue 1, pp. 93 - 102
Glioblastoma multiforme (GBM) is the most common malignant brain tumor in adults. Despite multiple treatment strategies. the prognosis is still poor. This... 
Panobinostat | BEZ235 | Glioblastoma | MEDICINE, RESEARCH & EXPERIMENTAL | CELLS | STRATEGY | RECURRENT GLIOBLASTOMA | NVP-BEZ235 | COMBINATION | panobinostat | MULTIFORME | VORINOSTAT | PHASE-II TRIAL | glioblastoma | HDAC | Original Paper
Journal Article
Molecular cancer therapeutics, ISSN 1535-7163, 4/2015, Volume 14, Issue 4, pp. 1014 - 1023
PI3K/AKT/mTOR pathway which is aberrantly stimulated in many cancer cells, has emerged as a target for therapy. However, mTORC1/S6K also mediates negative... 
PKI-587 | RAF | NVP-BEZ235 | GDC-0980 | Rictor | AKT | PD0325901
Journal Article
Journal of Central South University (Medical Sciences), ISSN 1672-7347, 08/2017, Volume 42, Issue 8, pp. 869 - 873
Journal Article
International Journal of Oncology, ISSN 1019-6439, 9/2014, Volume 45, Issue 3, pp. 1027 - 1035
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.